Vaxart (NASDAQ:VXRT) Share Price Crosses Below 200-Day Moving Average - Here's Why

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report)'s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.67 and traded as low as $0.29. Vaxart shares last traded at $0.31, with a volume of 3,171,336 shares changing hands.

Analyst Upgrades and Downgrades

Separately, B. Riley dropped their price objective on Vaxart from $2.50 to $2.00 and set a "buy" rating for the company in a report on Thursday, March 27th.

Vaxart Stock Up 13.3 %

The firm's fifty day moving average is $0.52 and its two-hundred day moving average is $0.65. The firm has a market cap of $81.29 million, a P/E ratio of -0.87 and a beta of 1.57.

Vaxart (NASDAQ:VXRT - Get Free Report) last announced its earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.05. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. The firm had revenue of $15.19 million for the quarter, compared to analyst estimates of $15.68 million. As a group, sell-side analysts forecast that Vaxart, Inc. will post -0.39 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. XTX Topco Ltd boosted its position in shares of Vaxart by 869.3% during the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock valued at $116,000 after purchasing an additional 122,387 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Vaxart by 15.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company's stock valued at $2,160,000 after buying an additional 346,725 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Vaxart in the 4th quarter worth about $129,000. Sequoia Financial Advisors LLC increased its stake in shares of Vaxart by 140.9% in the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 35,213 shares in the last quarter. Finally, Invesco Ltd. lifted its position in Vaxart by 48.6% during the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock valued at $50,000 after acquiring an additional 24,803 shares during the period. Institutional investors own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.